Discontinuation due to adverse events: TRIUMPH-2 placebo 4.9%, 4 mg 3.8%, 9 mg 11.6%, 12 mg 7.7% TRIUMPH-3 placebo 4.8%, 9 mg 9.8%, 12 mg 13.5% TRIUMPH-3s 13.5% is the highest figure we have for this molecule
The body needs time to adapt to each dose level, and GI side effects (nausea, decreased appetite, occasional diarrhea) tend to peak within the first 1-2 weeks of a new dose and then diminish
Darius M
What we do have is something arguably more meaningful: years of real-world evidence from thousands of physicians using these compounds under careful clinical supervision, with thousands of patients, over a decade or more
Looking for Market Leaders Only two companies, Eli Lilly and Novo Nordisk, have sizable GLP-1s available today, and we expect them to dominate the market over the intermediate term
A reduction in TKV was observed in the active treatment groups in contrast to placebo showing a slight but significant increase (Table 2, Fig